EIGHT OBSERVATIONS
ONE STRUCTURE
Oracle – AI infrastructure
Saks Global – Luxury retail
Ford Motor Company – Automotive
Crest Nicholson – Homebuilding
Alphabet – Big Tech
Novo Nordisk – Pharmaceuticals
Walgreens Boots Alliance – Healthcare
Intel Corporation – SemiconductorsIn each observation:The constraint was on the public record before the decision, and the company then set or restated a target while it was still in force.
Oracle
(AI Infrastructure Expansion)
Signal Environment (Q4 FY2024):► OCI consumption growth: +53% YoY (earnings call, June 11, 2024, third-party transcript)
► Growth constrained by infrastructure capacity
► CAPEX FY2024: $6.866BDisclosed: "Were it not for continuing supply constraints, consumption growth would have been even higher."
– Safra Catz, CEO, Q4 FY2024 earnings call, June 11, 2024 (third-party transcript; Oracle publishes no transcript of its calls)Disclosed the same day in the company's results release: "I also expect that each successive quarter should grow faster than the previous quarter—as OCI capacity begins to catch up with demand."
– Safra Catz, CEO, Oracle Q4 FY2024 results, June 11, 2024Condition: Constraint present ➔ not treated as limiting parameter.
Oracle
(AI Infrastructure Expansion)
Decision:FY2025 CAPEX guided to roughly double FY2024 (June 11, 2024)Outcome:► CAPEX: $6.9B (FY2024) → $21.2B (FY2025, 3.1x) → $55.7B (FY2026)
► FY2027 guidance: net cash outlay for capital expenditures of around $70B; reported CAPEX expected higher by around $20–25B (earnings call, June 10, 2026, third-party transcript)
► Free cash flow: –$23.7B (FY2026, company-reported)
► Headcount: ~162,000 → ~141,000 full-time employees (May 31, 2025 → May 31, 2026)Revised September 2026: decision restated to the company's June 2024 guidance; capital expenditure measures separated; analyst-consensus revenue line removed; headcount restated from the company's annual reports. Correction, 8 October 2026: the OCI consumption growth figure and the FY2027 guidance line come from third-party transcripts of the earnings calls. Both are now marked as such.
Saks Global
(Neiman Marcus Acquisition)
Signal Environment (before closing, December 2024):► Acquisition agreed July 4, 2024: total enterprise value $2.65B, funded by equity and debt facilities – a $1.15B term loan and a $2B asset-based revolving facility
► Vendor payment delays reported by brands – August 2024Reality signal – not a filing disclosure:
Brands reported unpaid invoices; at least one stopped shipping further inventory – visible before closing.
"Saks is committed to fulfilling its obligations to its vendor partners. Any delayed payments are due to navigating our business through the current challenging macroeconomic environment. No funds that otherwise support operations or vendor payables were used for the financing or associated costs of the proposed Neiman Marcus Group transaction."
– Saks spokesperson, quoted by Glossy, August 5, 2024Condition: Constraint present ➔ not treated as limiting parameter.
Saks Global
(Neiman Marcus Acquisition)
Decision:Acquisition closed December 23, 2024 – total enterprise value $2.7B, financed with $2.2B senior secured notes, a $1.8B asset-based revolving credit facility, $275M seller financing and new equity.Outcome:► Over $550M less in inventory receipts in the second half of 2025 than the company's July forecast
► Interest payments of about $126M due at the end of December 2025 not paid
► Chapter 11 petitions filed January 13–14, 2026
Ford Motor Company
(EV Transformation)
Signal Environment (FY2024-2025):► Model e (EV) EBIT: –$5.1B (2024)
► 2025 outlook: Model e EBIT loss of $5.0–5.5BDisclosed: "Ford Model e reported a full-year EBIT loss of $5.1 billion,
as the company continues to invest in future products. The segment
delivered $1.4 billion in cost improvements, net of a $100 million increase in spending to launch new battery plants and next-generation electric vehicles."
⎯ Ford Motor Company, Fourth-Quarter and Full-Year 2024 Results, February 5, 2025Condition: Constraint present ➔ priced into the company's own target.
Ford Motor Company
(EV Transformation)
Decision:► 2025 outlook issued the same day: Model e EBIT loss of $5.0–5.5B (February 5, 2025)Outcome:► Model e EBIT loss: –$849M (Q1), –$1.3B (Q2), –$1.4B (Q3 2025)
► December 15, 2025: "As part of these actions, Ford no longer plans to produce select larger electric vehicles where the business case has eroded due to lower-than-expected demand, high costs and regulatory changes."
► About $19.5B in special items announced; $15.5B recognized in Q4 2025
► Full-year 2025 net loss: –$8.2BAssessed against the priced-constraint criterion adopted on September 16, 2026: the disclosed constraint – the Model e loss – is priced in the company's own 2025 outlook. The observation was published before the criterion and is recorded as such. Correction, 8 October 2026: the 2025 Model e outlook was described as maintained. It was issued on February 5, 2025.
Crest Nicholson
(Forward Observation • Confirmed)
Signal Environment (January 2026):► Revenue: £610.8M (FY25, decline YoY)
► Net debt: £38.2M (31 Oct 2025, vs £8.5M prior year)
► Cash used by operations: £5.1M
► Open market sales rate: 0.53 in the first half of FY25 → 0.45 in the last 13 weeks of FY25; 0.51 for the year (FY24: 0.48)Disclosed: "In a severe but plausible downside scenario the Group is forecast to breach its interest cover covenant during the going concern period, with the first measurement date in April 2026. If this covenant breach were to occur, it would constitute an event of default under the terms of the revolving credit facility agreement and senior loan notes."
– Independent auditors' report, Annual Report and Accounts 2025Condition: Constraint present ➔ not treated as limiting parameter.
Crest Nicholson
(Forward Observation • Confirmed)
Decision:Forward guidance: £32–40M adjusted PBT, interest guided at £10–12M.
– Crest Nicholson, Final Results, January 29, 2026Observation published: March 24, 2026
Guidance restated as unchanged: AGM trading update, March 25, 2026
Outcome confirmed: April 21, 2026 (28 days later):► Temporary banking covenant relaxation sought
► Sales forecast cut from 1,550–1,700 to 1,400–1,500 units
► Land sales forecast cut from £75–100M to ~£40MH1 2026 results (July 16, 2026):► Adjusted operating result: £11.9M profit a year ago → £11.9M loss
► Revenue –20.8% to £197.6M
► Net debt £141.8M (vs £71.5M a year earlier)
► Interest-cover covenant waiver extended (measured 31 Aug 2026, reported by 30 Sept 2026)Trading update (September 3, 2026):
► EBIT guidance: loss of around £10M (previous guidance: profit of £5–10M)
► Completions guidance cut from 1,400–1,500 to 1,350–1,400
► Year-end net debt guidance improved to £70–90M (previous guidance: £100–120M), after land disposals and a fire remediation recovery
"The Group remains in constructive discussions with its lenders to amend its covenants and ensure that it has an appropriate level of funding and liquidity going forwards, although the Group now anticipates some slippage in the current timetable and will provide a further market update in due course."
– Crest Nicholson, Trading Update, September 3, 2026Constraint present ➔ not treated as limiting parameter.Correction, 8 October 2026: the FY25 cash line was named operating cash flow. The company’s line is cash used by operations. The waiver line no longer says “again”
Correction, 13 October 2026: the second-half sales rate of 0.49 was derived, not reported by the company. The line now gives the company’s figures: 0.53 in the first half of FY25 (half-year report, June 12, 2025), 0.45 in the last 13 weeks and 0.51 for the year (trading statement, November 18, 2025).
ALPHABET (GOOGLE)
AI Infrastructure
(Forward Observation • Confirmed)
Signal Environment (Q4 2025 results, February 4, 2026):► Supply constraints in AI compute capacity
► CAPEX growing faster than free cash flow
► Capital intensity acceleratingDisclosed:
"You know, you are right, and we've been supply-constrained, even as
we've been ramping up our capacity. Obviously, our CapEx spend this year is an eye towards the future; and you have to keep in mind some of the time horizons are increasing in the supply chain, et cetera. So, we are constantly planning for the long-term and working towards that. And, obviously, how we close the gap this year is a function of what we have done in the prior years. And so there is that time delay to keep in mind. I expect the demand we are seeing across the board, across our services, what we need to invest for future work for Google DeepMind, as well as for Cloud, I think is exceptionally strong. And so I do expect to go through the year in a supply-constrained way."
– Sundar Pichai, CEO, Q4 2025 Earnings Call, February 4, 2026Disclosed again, five days after the observation was published: "Obviously, we are compute constrained in the near term. And as an example, our Cloud revenue would have been higher if we were able to meet the demand. So we are working through that moment and we are investing, but we have a robust long range planning framework, and we see extraordinary opportunities ahead, and we are allocating with that framework in mind."
– Sundar Pichai, CEO, Q1 2026 Earnings Call, April 29, 2026.Condition: Constraint present ➔ not treated as limiting parameter.
ALPHABET (GOOGLE)
AI Infrastructure
(Forward Observation • Confirmed)
Decision at the time of observation:► CAPEX 2026: $175–185B guided
► Nearly double 2025 ($91.4B)
► Over 5x 2023 levels ($32.25B)Observation published: April 24, 2026Decision after the observation:"Moving to investment, we are updating our full year 2026 CapEx guidance range to $180 to $190 billion, up from our previous estimate of $175 to $185 billion, to now include investment related to the acquisition of Intersect, which closed in March."
"Looking ahead, these strong results reinforce our conviction to invest the capital required to continue to capture the AI opportunity. As a result, we expect our 2027 CapEx to significantly increase compared to 2026."
⎯ Anat Ashkenazi, CFO, Q1 2026 Earnings Call, April 29, 2026Outcome confirmed: July 22, 2026 (89 days after the observation)
– Q2 2026 results:► Free cash flow: negative $5.9B – the first negative quarterly free cash flow in at least 18 years of reported results; a reversal from positive $10.1B the prior quarter
► CAPEX: $44.9B, up 100% year over year – a record quarter
► Full-year 2026 CAPEX guidance raised again to $195–205B
► Constraint named again on the second-quarter 2026 earnings call, July 22, 2026 – CFO Anat Ashkenazi:"Thanks for the question on how do we think about forward-looking CapEx in the context of supply constraints. So, we're still in a supply-constrained environment. I think we've said this now for multiple quarters in a row. And we are seeing very strong demand, both from external Cloud customers as well as across the business. And our goal is to invest as long as we see an attractive return on that investment, as Sundar mentioned earlier. We do take a long-term view, so we take a multiyear view, at what the needs are, as well as focus on next year in the near term and building aggressively to meet those demands. And as you've seen, while we have increased our capacity quite significantly over the past three years, the demand still outpaces that investment. And we are, just like the rest of the industry, working in a supply-constrained environment, so we're working hard to do this. We do have a benefit of having a full-stack approach, so we're able to drive operational efficiencies, technological efficiencies within our technical infrastructure organization so that we can deliver more compute. But as long as we see these attractive opportunities to invest, we will continue to invest."Constraint present ➔ not treated as limiting parameter. The cost followed.
Revised September 2026: quotations restored in full from the company's transcripts; guidance wording, free cash flow record and constraint count corrected.
NOVO NORDISK
GLP-1 Pricing Pressure
Forward Observation • Open
Signal Environment (FY2025 results and 2026 outlook, February 3, 2026):► Lower realised prices on semaglutide medicines, including Wegovy and Ozempic
► MFN agreement in the US reflected in the 2026 outlook
► Adjusted sales and adjusted operating profit growth guidance 2026: –5% to –13% at CER – raised May 6, 2026 to –4% to –12%. Negative both times.
► CEO change: announced May 16, 2025; new CEO effective August 7, 2025Disclosed:
"The outlook reflects expectations for sales growth within International Operations and expectations for a sales decline within US Operations. In 2026, the global GLP-1 market expansion is assumed to continue, enabling Novo Nordisk to increase patient reach and expand volumes. This is countered by lower realised prices, including the MFN ('Most Favoured Nations') agreement in the US and the loss of exclusivity for the semaglutide molecule in certain markets in International Operations. Lastly, positive impacts related to US gross-to-net sales adjustments during 2025 are not anticipated to reoccur."
– Novo Nordisk, 2026 outlook, February 3, 2026Condition: Constraint present ➔ priced into the company's own target.
NOVO NORDISK
GLP-1 Pricing Pressure
Forward Observation • Open
Decision:"Capital expenditure is expected to be around DKK 55 billion in 2026 compared to DKK 60 billion in 2025, reflecting the expansion of the global supply chain. The investments will create additional capacity and flexibility across the supply chain, including the manufacturing of active pharmaceutical ingredients (API), additional aseptic production and finished production processes as well as packaging capacity. In the coming years, the capital expenditure investments are expected to decline."
– Novo Nordisk, Financial report for 2025, February 3, 2026► CAPEX guidance of around DKK 55B repeated on May 6 and August 4, 2026
► Production expansion under way: Kalundborg (approx. DKK 49.6B), Clayton (approx. DKK 27.0B), Hillerød (approx. DKK 15.9B) – expected expenditures per the 2025 annual reportObservation published: June 12, 2026Data point: August 4, 2026 – Q2 2026 results:► Adjusted operating profit: DKK 33,389M, +11% at CER
► 2026 adjusted sales and adjusted operating profit growth guidance raised to 0% to –6% at CER, from –4% to –12%
► "Adjusted gross margin was realised at 78.2%, compared with 82.7% in Q2 2025. The decline in gross margin is impacted by lower realised prices, one-time costs of around DKK 3 billion related to right-sizing of manufacturing capacity agreements, as well as a negative currency impact. This was partly countered by productivity gains and a positive product mix from increased GLP-1 sales."
► CAPEX guidance unchanged at around DKK 55B
► Bridge pilot programme – Medicare Part D coverage for obesity medicines – implemented from July 1, 2026The cost has not materialised at this data point. The constraint remains disclosed.Outcome: Open. Next data point: November 4, 2026 – nine-month results.Revised September 2026: the disclosed passage is quoted in full; the company's capital expenditure and gross margin statements are quoted in full; the Bridge programme is described in the company's words.
Assessed against the priced-constraint criterion adopted on September 16, 2026: the disclosed constraint – lower realised prices, including the MFN agreement – is reflected in the company's own 2026 outlook. The observation was published before the criterion and is recorded as such. Correction, 8 October 2026: the capital expenditure passage of February 3, 2026 was quoted with its middle sentence omitted. It now stands in full.
WALGREENS BOOTS ALLIANCE
Healthcare Transformation
Signal Environment (October 13, 2022):► U.S. Healthcare segment operating loss: –$338M reported, –$151M adjusted (Q4 FY2022)
► Segment guided to an adjusted EBITDA loss of $220–240M for fiscal 2023 (earnings call, October 13, 2022, third-party transcript)Target set in the same release:"Raising U.S. Healthcare fiscal 2025 sales target to $11 billion to $12 billion, with the segment expected to achieve positive adjusted EBITDA by fiscal year 2024"
– Walgreens Boots Alliance, Fiscal Year 2022 results release, October 13, 2022Condition: Constraint present ➔ priced into the company's own target.
WALGREENS BOOTS ALLIANCE
Healthcare Transformation
Decision – on the same day:"With our solid execution to-date and greater visibility ahead, we are increasing our fiscal 2025 sales goal from $9 billion to $10 billion previously to $11 to $12 billion and representing a compound annual growth rate of approximately 50% on a pro forma basis."
– James Kehoe, CFO, Q4 FY2022 Earnings Call, October 13, 2022 (third-party transcript)Outcome:► $12.4B non-cash impairment charge related to VillageMD goodwill – $5.8B after tax (Q2 FY2024)
► CEO Rosalind Brewer stepped down – announced September 1, 2023
► Closure of approximately 160 VillageMD clinics approved – fiscal 2024
► Approximately 1,200 store closures announced over three years – October 2024
► Taken private by Sycamore Partners – August 28, 2025Revised September 2026: signal lines not documented on October 13, 2022 removed; quotations replaced with the company's own wording; outcome figures restated to the company's filings. Assessed against the priced-constraint criterion adopted on September 16, 2026: the disclosed constraint – the segment loss – is priced in the company's own target (positive adjusted EBITDA by fiscal 2024). The observation was published before the criterion and is recorded as such. Correction, 8 October 2026: the CFO quotation and the fiscal 2023 guidance line come from a third-party transcript of the earnings call. Both are now marked as such.
INTEL CORPORATION
(Foundry Capacity Commitment)
Signal Environment (April 2, 2024 – Intel Foundry reported as a separate operating segment for the first time):► Intel Foundry revenue FY2023: $18,910M
► Intel Foundry operating loss FY2023: –$6,955M
► Recast segment results published for 2023, 2022 and 2021
► Intel capital assets: approximately $100 billionDisclosed – external demand, in the company's own figure, in the same sentence as the goal:"Intel Foundry currently has an expected lifetime deal value with external customers of more than $15 billion and remains focused on its goal of becoming the world's second-largest foundry by 2030."
– Intel Corporation, Intel Foundry financial framework announcement, April 2, 2024Condition: Constraint present ➔ not treated as limiting parameter.
INTEL CORPORATION
(Foundry Capacity Commitment)
Decision – stated in the same announcement:"Intel Foundry's operating losses are expected to peak in 2024 as Intel completes its five-nodes-in-four-years journey, and the company is driving for Intel Foundry to achieve break-even operating margins midway between now and the end of 2030, when it targets 40% non-GAAP gross margins and 30% non-GAAP operating margins."
"The transition to the new operating model is expected to enable Intel Foundry to achieve profitable growth and unlock unrealized value across Intel's approximately $100 billion in capital assets. It will also create significant efficiency and cost savings opportunities across both Intel Foundry and Intel Products."
– Intel Corporation, Intel Foundry financial framework announcement, April 2, 2024Outcome:► Intel Foundry operating loss: –$13,291M (FY2024), –$10,318M (FY2025), as reported in the 2025 Annual Report
► Group operating loss: –$11,678M (FY2024), –$2,214M (FY2025)
► Core workforce: approximately 15% reduction under the 2025 Restructuring Plan; about 75,000 core employees targeted by year end – July 24, 2025
► Previously planned projects in Germany and Poland cancelled; construction in Ohio further slowed – July 24, 2025The company's own account: "We will take a fundamentally different approach to building our foundry business. Over the past several years, the company invested too much, too soon – without adequate demand. In the process, our factory footprint became needlessly fragmented and underutilized. We must correct our course."
– Lip-Bu Tan, Chief Executive Officer, Intel Corporation, message to employees, July 24, 2025Revised September 2026: the disclosed constraint is stated as external demand, as in the original observation; the company's loss and break-even plan is shown as part of the decision; segment losses are given on one reporting basis; workforce figures restated to the company's wording; quotations completed to full paragraphs.
PATTERN DETECTED
In each of the eight observations:The constraint was on the public record before the decision – in the company's own filings, on its own calls, in its own auditor's report, or in the conduct of its own suppliers.
The company then set or restated a target while that constraint was still in force.⬇︎In five, the target did not carry the constraint. In three, it did.
Seven observations have resolved with a cost. One remains live.
CONTROL OBSERVATION – META (2022–2023)
The same structural condition – and the decision changed.Signal Environment (2022):► Headcount grew approximately 50% – from 58,604 (December 31, 2020) to 87,314 (September 30, 2022)
► Q2 2022: first year-over-year revenue decline in company history – $28.82B vs $29.08B
► Q3 2022: revenue fell 4.5% – costs and expenses grew 19% in the same quarter
► Reality Labs operating loss: $13.7B in 2022 alone
► Free cash flow: down 52% in one year – $38.4B (2021) to $18.4B (2022)The decision continued on October 26, 2022, with the third-quarter results:
"For 2023, we expect capital expenditures to be in the range of $34-39 billion, driven by our investments in data centers, servers, and network infrastructure."
"We do anticipate that Reality Labs operating losses in 2023 will grow significantly year-over-year."
– Meta Platforms, Third Quarter 2022 Results, October 26, 2022Disclosed, 14 days later: "At the start of Covid, the world rapidly moved online and the surge of e-commerce led to outsized revenue growth. Many people predicted this would be a permanent acceleration that would continue even after the pandemic ended. I did too, so I made the decision to significantly increase our investments. Unfortunately, this did not play out the way I expected. Not only has online commerce returned to prior trends, but the macroeconomic downturn, increased competition, and ads signal loss have caused our revenue to be much lower than I'd expected. I got this wrong, and I take responsibility for that."
– Mark Zuckerberg, message to Meta employees, November 9, 2022The correction came after cost materialized – not before. The sequence was interrupted, not prevented.
CONTROL OBSERVATION – META (2022–2023)
Decision – the constraint was applied:► About 21,000 positions: more than 11,000 announced November 9, 2022; around 10,000 announced March 14, 2023
► 2023 CAPEX guidance: $34–39B → $34–37B (November 9, 2022) → $30–33B (February 1, 2023)
► Headcount reduced from 87,314 (September 30, 2022) to 66,185 (September 30, 2023)Constraint present. Constraint disclosed. Treated as a limiting parameter, and the decision changed.Revised September 2026: the October 26, 2022 guidance is shown as the decision before the correction; capital expenditure guidance is given in the order the company issued it; the November 9, 2022 quotation appears as the full paragraph.
PAIRED COMPARISON
TAYLOR WIMPEY / CREST NICHOLSON
The same market. The same year. A constraint named on the record in each. The opposite decision.TAYLOR WIMPEY (UK Housebuilding)Disclosed: "We expect market conditions to remain challenging for the remainder of the year, with underlying pricing below prior year levels and full year build cost inflation of c.3-4%."
⎯ Taylor Wimpey plc, Half Year Results 2026, July 31, 2026Decision – the company drew the line from the constraint to the number: "Reflecting the lower first half sales rate and ongoing market backdrop, we expect UK completions excluding joint ventures for the full year to be between 10,600 and 10,800 homes, within the lower half of the range provided in March. Blended UK average selling prices are expected to be around 1% higher than last year, due mainly to regional and product mix. H2 2026 Group net operating expenses are expected to be broadly in line with the first half, with net finance costs for the full year of c.£25 million."
⎯ Taylor Wimpey plc, Half Year Results 2026, July 31, 2026► "Updated Distribution Policy announced today, revising annual shareholder returns to 4% of net assets to reflect the prolonged market downturn, preserve balance sheet strength and retain financial flexibility"
► Total Group completions including joint ventures: 4,986 homes (H1 2025: 5,264 homes)CREST NICHOLSON (in this record)► Interest cover covenant named by the auditors, first measurement date April 2026.
► Forward guidance: £32–40M adjusted PBT, Final Results, January 29, 2026; restated as unchanged, AGM trading update, March 25, 2026.
► April 21, 2026: guidance moved to EBIT of £5–15M, with interest costs of c. £15M; the company said it was "in the early stages of seeking temporary banking covenant relaxation".Taylor Wimpey: constraint present, constraint disclosed, treated as a limiting parameter. The target was moved to the constraint, in the same document that named it.Crest Nicholson: constraint present, constraint disclosed, not treated as a limiting parameter.Revised September 2026: the comparison no longer describes the two constraints as the same class; the Taylor Wimpey guidance paragraph and distribution policy are quoted in the company's words; the Crest Nicholson lines are restated to the company's announcement and an unsourced share-price figure is removed.
FINAL DIAGNOSTIC STATEMENT
Eight observations are in the record. In each, the constraint was on the public record before the decision: in the company's own filings, on its own calls, in its own auditor's report, or in the conduct of its own suppliers. In five of them, the target the company set did not price it in: Oracle, Saks Global, Crest Nicholson, Alphabet and Intel. In the other three, the company's own target did price it in: Ford, Walgreens and Novo Nordisk. These three were published before the priced-constraint criterion adopted on September 16, 2026, and are recorded as such.
WHAT THIS RECORD DOES NOT CLAIM
The record states no cause, and makes no statement about how often the sequence occurs. It documents observations in which a constraint was on the public record before the decision, in one of the four places named above, and the company then set or restated a target while that constraint was still in force. Two companies that faced a named constraint and applied it appear on this page: Taylor Wimpey and Meta. Neither is one of the eight observations, because in both the constraint was applied. Meta is carried on this page as a control observation.
SOURCE SET (Public)
► Public filings
► Earnings calls and transcripts
► Earnings releases
► Company announcements and CEO letters
► Auditor reports
► SEC / RNS filings
► Court filings
► A company statement carried in the trade press (one statement, marked on the Saks Global card)Each of the eight observations carries its date and the documents it rests on.
DEPOSIT
The document and its source appendix are deposited at:
SSRN
The document is posted at:
Disclaimer: This page records publicly available information about the companies named. Not investment advice.